poisar

Stock

Aktis Oncology, Inc. AKTS

$24.15+1.51%

Overview

AKTS market data

Price History

AKTS price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.26
Diluted earnings per share over the trailing twelve months.
Beta
119.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-843.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$14.72 – $34.19
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 5.88 · P/S 137.00.

Company News

8 captured
Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below HighsBenzinga · Aug 14, 2026, 3:02 PM
Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M EstimateBenzinga · Aug 13, 2026, 8:56 PM
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33Benzinga · Jul 14, 2026, 1:43 PM
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 7, 2026, 2:05 PM
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For TuesdayBenzinga · Jun 16, 2026, 11:20 AM
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On FridayBenzinga · Jun 12, 2026, 2:15 PM
HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35Benzinga · Jun 2, 2026, 5:00 PM
Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 Radiopharmaceutical Data Presented At ASCO 2026Benzinga · May 21, 2026, 9:30 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock